Author: Alison James


Coulter Partners recently talked to Cristina Duran, Chief Digital Health Officer in R&D for AstraZeneca about digital disruption and talent in healthcare. “In other industries such as banking or retail, a focus on customers has always been key to the success of digital transformation. For pharmaceuticals it is the same. We focus on the patient and listen to what they want or need. We put the patient at the centre, listening to feedback on their experience of a clinical trial, for instance – the good and the bad. We are working together with patients and physicians in all our disease areas of focus to clarify the potential health outcomes of different treatment pathways.”

Coulter Partners secures Supervisory Board Directors for Pharming Group

Paul Sekhri, Chairman of the Board of Supervisory Directors: “We are thrilled to nominate Barbara Yanni and Mark Pykett as new members of the Board of Supervisory Directors. Their extensive experience and strong track record in pharmaceuticals and biotechnology in the US complements the existing expertise of our Board. Accordingly, they will further strengthen the Board’s ability to effectively oversee Pharming’s fast-growing global business activities, especially those in the increasingly important US market and I thank the team at Coulter Partners for their professional support in achieving these key nominations.”


“Medopad rebrands as Huma as it expands offerings and acquires AI and wearable tech startups.” –
Coulter Partners talked recently to Tamir Strauss, Head of Customer Solutions at Huma about digital disruption and talent in healthcare: “I think if regulators were able to combine the fundamental need to keep patients safe with the understanding that the world of software development is evolving rapidly, then innovation would explode across all areas of this industry.”

Coulter Partners secures Chief Commercial Officer for Albumedix

Coulter Partners was delighted to partner once again with Albumedix, the world leader in recombinant human albumin (rAlb), to secure the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy.


“Novadiscovery raises series A financing to scale its in silico clinical trial platform – Debiopharm leads the round with EUR 5 million” –
Coulter Partners recently talked to CEO and Co-Founder, Francois-Henri Boissel of Nova on digital disruption and talent in healthcare.

Coulter Partners secures Chief Medical Officer for Saniona

Coulter Partners was very pleased to partner recently with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner brings more than 20 years of experience leading multiple pharmaceutical development programs from discovery through approval and launch, in both large and small pharmaceutical companies.


Coulter Partners talked recently to Karen Taylor, Research Director with the Deloitte Centre for Health Solutions, about Digital Disruption in Healthcare. “Digital Health providers need to do it with patients and not to patients,” is key advice she would give them.


“Digital front opens in war on Covid-19 as start-ups come to aid of NHS” “Video Consultations available to 5.3 million patients in Britain on the NHS” “Push Doctor aims to run online service in 500 practices by the end of 2020”
Coulter Partners recently talked to CEO, Wais Shaifta of Push Doctor on digital disruption and talent in healthcare.